Aytu BioPharma (NASDAQ:AYTU) Issues Earnings Results, Misses Estimates By $0.37 EPS

Aytu BioPharma (NASDAQ:AYTU) issued its quarterly earnings data on Thursday. The company reported ($0.82) EPS for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.37), Zacks reports. Aytu BioPharma had a negative net margin of 14.60% and a negative return on equity of 31.31%. The company had revenue of $17.98 million for the quarter.

Aytu BioPharma Stock Performance

Aytu BioPharma stock traded down $0.49 during mid-day trading on Friday, reaching $2.36. The company’s stock had a trading volume of 237,675 shares, compared to its average volume of 20,737. The business’s 50 day simple moving average is $2.52 and its 200 day simple moving average is $2.82. The company has a market capitalization of $14.09 million, a price-to-earnings ratio of -0.90 and a beta of -1.43. Aytu BioPharma has a 12 month low of $1.87 and a 12 month high of $3.50.

About Aytu BioPharma

Aytu Biopharma, Inc, a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old.